Paul Cossum

Biography

Paul Cossum has more than 20 years of experience in the biotechnology industry. He began his career as a scientist in the Pharmacological Sciences Department at Genentech Inc. There he worked on the metabolism and toxicity of recombinant human proteins, as well as peptides, in support of new therapeutics entering clinical trials. Over the next two decades he assumed increasingly broader roles and responsibilities in drug development at Isis Pharmaceuticals, Aronex Pharamceuticals and Newbiotics Pharmaceuticals. Most recently Paul was President and CEO of Proacta Inc., an early stage oncology focused discovery and development company. Much of his experience has focused on the interface between discovery and development, although he has also been responsible for preclinical sections of New Drug Applications (NDAs). Therapeutic areas of knowledge include inflammation, oncology, anti-infectives, cardiovascular, neurology and endocrinology. He has experience with small molecules, recombinant proteins, peptides, oligonucleotides, monoclonal antibodies and gene therapy. Paul holds Bachelor, Masters and PhD degrees from the University of Tasmania, Australia.

Research Interest

Healthcare